These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16892907)

  • 41. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT).
    Scheifele D; Halperin S; Pelletier L; Talbot J
    Clin Infect Dis; 2000 Jul; 31(1):58-64. PubMed ID: 10913397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
    Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Conjugated vaccines].
    Swennen B; Sternon J
    Rev Med Brux; 2002 Jun; 23(3):165-74. PubMed ID: 12143156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine.
    Obando I; Arroyo LA; Sánchez-Tatay D; Tarragó D; Moreno D; Hausdorff WP; Brueggemann AB
    Clin Microbiol Infect; 2007 Mar; 13(3):347-8. PubMed ID: 17391398
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pneumococcal conjugate vaccine in children].
    Lévy J; Swennen B
    Rev Med Brux; 2004 Sep; 25(4):A219-22. PubMed ID: 15516044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nasopharyngeal colonization: a target for pneumococcal vaccination.
    Käyhty H; Auranen K; Nohynek H; Dagan R; Mäkelä H
    Expert Rev Vaccines; 2006 Oct; 5(5):651-67. PubMed ID: 17181439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pneumococcal conjugated vaccine: PHiD-CV.
    Dinleyici EC; Yargic ZA
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pneumococcal conjugate vaccine for young children.
    Zimmerman RK
    Am Fam Physician; 2001 May; 63(10):1991-8. PubMed ID: 11388715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of conjugate pneumococcal vaccine by United Kingdom neonatal intensive care units.
    Moss SJ; Fenton AC; Gennery AR
    Arch Dis Child Fetal Neonatal Ed; 2005 Mar; 90(2):F187-8. PubMed ID: 15724056
    [No Abstract]   [Full Text] [Related]  

  • 56. Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008.
    Wkly Epidemiol Rec; 2008 Oct; 83(43):388-92. PubMed ID: 18949860
    [No Abstract]   [Full Text] [Related]  

  • 57. Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000–2012.
    Wkly Epidemiol Rec; 2013 Apr; 88(17):173-80. PubMed ID: 23696979
    [No Abstract]   [Full Text] [Related]  

  • 58. Assessing non-inferiority to an aggregate response with an application to development of pneumococcal conjugate vaccines.
    Pan Y; Liu GF; Dallas MJ
    Pharm Stat; 2011; 10(4):332-40. PubMed ID: 21061417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumococcal disease in childhood.
    Mohan PV; Heath PT
    Hosp Med; 2001 Jul; 62(7):406-9. PubMed ID: 11480127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ACIP extends delay in pneumococcal immunization of healthy children.
    Am J Health Syst Pharm; 2002 Feb; 59(3):228. PubMed ID: 11862630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.